US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip Bandyopadhyay

The pharma sector is currently experiencing volatility, with Nifty Pharma weighing on the broader market. US tariffs on branded drugs could exacerbate existing pricing pressures and regulatory scrutiny.

Maintain a cautious stance on pharma stocks with high branded drug exposure; consider defensive plays or companies with strong domestic focus and diversified product pipelines.

For Indian markets, this story mainly matters for VEDL, NATIONALUM, TATASTEEL and the Metals & Mining, Pharmaceuticals pocket. The current signal is bearish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Well-positioned in aluminium despite US tariffs. Well-positioned in aluminium despite US tariffs. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Indian equity markets face policy risks from US tariffs and West Asia conflict.
• •These issues impact metals and pharmaceutical sectors.
• •Sudip Bandyopadhyay provides stock-specific insights.
• •Vedanta and NALCO are well-positioned in aluminium.
• •Tata Steel faces uncertainty due to European operations.